• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于检测阿尔茨海默病的新型载脂蛋白E4天然结构校正剂:高通量筛选和分子动力学模拟的成果

Novel natural structure corrector of ApoE4 for checking Alzheimer's disease: benefits from high throughput screening and molecular dynamics simulations.

作者信息

Goyal Manisha, Grover Sonam, Dhanjal Jaspreet Kaur, Goyal Sukriti, Tyagi Chetna, Chacko Sajeev, Grover Abhinav

机构信息

Apaji Institute of Mathematics & Applied Computer Technology, Banasthali University, Tonk, Rajasthan 304022, India.

出版信息

Biomed Res Int. 2013;2013:620793. doi: 10.1155/2013/620793. Epub 2013 Nov 13.

DOI:10.1155/2013/620793
PMID:24324968
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3845489/
Abstract

A major genetic suspect for Alzheimer's disease is the pathological conformation assumed by apolipoprotein E4 (ApoE4) through intramolecular interaction. In the present study, a large library of natural compounds was screened against ApoE4 to identify novel therapeutic molecules that can prevent ApoE4 from being converted to its pathological conformation. We report two such natural compounds PHC and IAH that bound to the active site of ApoE4 during the docking process. The binding analysis suggested that they have a strong mechanistic ability to correct the pathological structural orientation of ApoE4 by preventing repulsion between Arg 61 and Arg 112, thus inhibiting the formation of a salt bridge between Arg 61 and Glu 255. However, when the molecular dynamics simulations were carried out, structural changes in the PHC-bound complex forced PHC to move out of the cavity thus destabilizing the complex. However, IAH was structurally stable inside the binding pocket throughout the simulations trajectory. Our simulations results indicate that the initial receptor-ligand interaction observed after docking could be limited due to the receptor rigid docking algorithm and that the conformations and interactions observed after simulation runs are more energetically favored and should be better representations of derivative poses in the receptor.

摘要

阿尔茨海默病的一个主要基因嫌疑对象是载脂蛋白E4(ApoE4)通过分子内相互作用所呈现的病理构象。在本研究中,针对ApoE4筛选了一个大型天然化合物库,以鉴定能够防止ApoE4转变为其病理构象的新型治疗分子。我们报告了两种这样的天然化合物PHC和IAH,它们在对接过程中与ApoE4的活性位点结合。结合分析表明,它们具有强大的机制能力,可通过防止精氨酸61和精氨酸112之间的排斥来纠正ApoE4的病理结构取向,从而抑制精氨酸61和谷氨酸255之间盐桥的形成。然而,当进行分子动力学模拟时,与PHC结合的复合物的结构变化迫使PHC移出腔,从而使复合物不稳定。然而,在整个模拟轨迹中,IAH在结合口袋内结构稳定。我们的模拟结果表明,对接后观察到的初始受体 - 配体相互作用可能因受体刚性对接算法而受到限制,并且模拟运行后观察到的构象和相互作用在能量上更有利,应该是受体中衍生姿势的更好表示。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/681e/3845489/2049ab21d583/BMRI2013-620793.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/681e/3845489/fe5d7028fea4/BMRI2013-620793.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/681e/3845489/16a2e0514236/BMRI2013-620793.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/681e/3845489/ba76fecf5de7/BMRI2013-620793.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/681e/3845489/2c2b23bfa39e/BMRI2013-620793.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/681e/3845489/2049ab21d583/BMRI2013-620793.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/681e/3845489/fe5d7028fea4/BMRI2013-620793.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/681e/3845489/16a2e0514236/BMRI2013-620793.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/681e/3845489/ba76fecf5de7/BMRI2013-620793.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/681e/3845489/2c2b23bfa39e/BMRI2013-620793.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/681e/3845489/2049ab21d583/BMRI2013-620793.005.jpg

相似文献

1
Novel natural structure corrector of ApoE4 for checking Alzheimer's disease: benefits from high throughput screening and molecular dynamics simulations.用于检测阿尔茨海默病的新型载脂蛋白E4天然结构校正剂:高通量筛选和分子动力学模拟的成果
Biomed Res Int. 2013;2013:620793. doi: 10.1155/2013/620793. Epub 2013 Nov 13.
2
Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons.小分子结构校正剂可消除载脂蛋白 E4 在培养神经元中的有害影响。
J Biol Chem. 2012 Feb 17;287(8):5253-66. doi: 10.1074/jbc.M111.276162. Epub 2011 Dec 12.
3
Lipidated apolipoprotein E4 structure and its receptor binding mechanism determined by a combined cross-linking coupled to mass spectrometry and molecular dynamics approach.通过结合交联技术结合质谱和分子动力学方法研究载脂蛋白 E4 的结构及其受体结合机制。
PLoS Comput Biol. 2018 Jun 22;14(6):e1006165. doi: 10.1371/journal.pcbi.1006165. eCollection 2018 Jun.
4
Fragment-Based Discovery of an Apolipoprotein E4 (apoE4) Stabilizer.基于片段的载脂蛋白 E4(apoE4)稳定剂的发现。
J Med Chem. 2019 Apr 25;62(8):4120-4130. doi: 10.1021/acs.jmedchem.9b00178. Epub 2019 Apr 12.
5
Concerning the structure of apoE.关于 apoE 的结构。
Protein Sci. 2013 Dec;22(12):1820-5. doi: 10.1002/pro.2379. Epub 2013 Oct 19.
6
Molecular Mechanisms of the R61T Mutation in Apolipoprotein E4: A Dynamic Rescue.载脂蛋白E4中R61T突变的分子机制:动态挽救
Biophys J. 2017 Nov 21;113(10):2192-2198. doi: 10.1016/j.bpj.2017.08.026. Epub 2017 Sep 12.
7
Cognitive deficits and disruption of neurogenesis in a mouse model of apolipoprotein E4 domain interaction.载脂蛋白 E4 结构域相互作用的小鼠模型中的认知缺陷和神经发生障碍。
J Biol Chem. 2014 Jan 31;289(5):2946-59. doi: 10.1074/jbc.M113.497909. Epub 2013 Dec 9.
8
Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease.载脂蛋白 E4 结构域相互作用介导对线粒体的有害影响,是阿尔茨海默病的潜在治疗靶点。
J Biol Chem. 2011 Feb 18;286(7):5215-21. doi: 10.1074/jbc.M110.151084. Epub 2010 Nov 30.
9
Proposal of novel ApoE4 inhibitors from the natural spice Cinnamon for the treatment of Alzheimer's disease: Ab initio molecular simulations.从天然香料肉桂中提出新型载脂蛋白 E4 抑制剂用于治疗阿尔茨海默病:从头分子模拟。
Biophys Chem. 2023 May;296:106990. doi: 10.1016/j.bpc.2023.106990. Epub 2023 Mar 5.
10
The Molecular Basis for Apolipoprotein E4 as the Major Risk Factor for Late-Onset Alzheimer's Disease.载脂蛋白 E4 作为晚发性阿尔茨海默病主要危险因素的分子基础。
J Mol Biol. 2019 May 31;431(12):2248-2265. doi: 10.1016/j.jmb.2019.04.019. Epub 2019 Apr 30.

引用本文的文献

1
Perspectives on the Role of as a Therapeutic Target for Alzheimer's Disease.关于[具体内容]作为阿尔茨海默病治疗靶点作用的观点。 (你提供的原文中“Perspectives on the Role of ”后面似乎缺少具体内容)
J Alzheimers Dis Rep. 2021 Dec 27;5(1):899-910. doi: 10.3233/ADR-210027. eCollection 2021.
2
Identification of GCC-box and TCC-box motifs in the promoters of differentially expressed genes in rice (Oryza sativa L.): Experimental and computational approaches.鉴定水稻差异表达基因启动子中的 GCC-box 和 TCC-box 基序:实验和计算方法。
PLoS One. 2019 Apr 26;14(4):e0214964. doi: 10.1371/journal.pone.0214964. eCollection 2019.
3

本文引用的文献

1
Incidence of Alzheimer's disease in India: a 10 years follow-up study.印度阿尔茨海默病的发病率:一项为期 10 年的随访研究。
Neurol India. 2012 Nov-Dec;60(6):625-30. doi: 10.4103/0028-3886.105198.
2
Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer's disease.载脂蛋白 E3 和载脂蛋白 E4 之间的结构差异可能有助于开发阿尔茨海默病的治疗药物。
Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):8913-8. doi: 10.1073/pnas.1207022109. Epub 2012 May 21.
3
2012 Alzheimer's disease facts and figures.
ApoE: In Vitro Studies of a Small Molecule Effector.
载脂蛋白E:一种小分子效应物的体外研究
Biochemistry. 2016 May 10;55(18):2613-21. doi: 10.1021/acs.biochem.6b00324. Epub 2016 Apr 27.
4
Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.关于HIV-1蛋白酶非活性位点突变V77I导致奈非那韦耐药性分子机制的结构研究
BMC Bioinformatics. 2015;16 Suppl 19(Suppl 19):S10. doi: 10.1186/1471-2105-16-S19-S10. Epub 2015 Dec 16.
5
Structural investigations of T854A mutation in EGFR and identification of novel inhibitors using structure activity relationships.表皮生长因子受体(EGFR)中T854A突变的结构研究及利用构效关系鉴定新型抑制剂
BMC Genomics. 2015;16 Suppl 5(Suppl 5):S8. doi: 10.1186/1471-2164-16-S5-S8. Epub 2015 May 26.
6
Fragment based group QSAR and molecular dynamics mechanistic studies on arylthioindole derivatives targeting the α-β interfacial site of human tubulin.基于片段的基团定量构效关系及分子动力学机理研究:针对靶向人微管蛋白α-β界面位点的芳硫基吲哚衍生物
BMC Genomics. 2014;15 Suppl 9(Suppl 9):S3. doi: 10.1186/1471-2164-15-S9-S3. Epub 2014 Dec 8.
2012 年阿尔茨海默病事实和数据。
Alzheimers Dement. 2012;8(2):131-68. doi: 10.1016/j.jalz.2012.02.001.
4
Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons.小分子结构校正剂可消除载脂蛋白 E4 在培养神经元中的有害影响。
J Biol Chem. 2012 Feb 17;287(8):5253-66. doi: 10.1074/jbc.M111.276162. Epub 2011 Dec 12.
5
Virtual fragment docking by Glide: a validation study on 190 protein-fragment complexes.通过 Glide 进行虚拟片段对接:对 190 个蛋白-片段复合物的验证研究。
J Chem Inf Model. 2010 Jun 28;50(6):1165-72. doi: 10.1021/ci1000407.
6
The role of apolipoprotein E in Alzheimer's disease.载脂蛋白E在阿尔茨海默病中的作用。
Neuron. 2009 Aug 13;63(3):287-303. doi: 10.1016/j.neuron.2009.06.026.
7
Commentary on "Perspective on a pathogenesis and treatment of Alzheimer's disease." Apolipoprotein E and the mitochondrial metabolic hypothesis.关于“阿尔茨海默病发病机制与治疗的展望”的评论。载脂蛋白E与线粒体代谢假说。
Alzheimers Dement. 2006 Apr;2(2):71-3. doi: 10.1016/j.jalz.2005.12.006.
8
Perspective on a pathogenesis and treatment of Alzheimer's disease.阿尔茨海默病的发病机制与治疗展望
Alzheimers Dement. 2006 Apr;2(2):59-70. doi: 10.1016/j.jalz.2005.12.001.
9
Alzheimer disease: multiple causes, multiple effects of apolipoprotein E4, and multiple therapeutic approaches.阿尔茨海默病:多种病因、载脂蛋白E4的多种作用及多种治疗方法。
Ann Neurol. 2009 Jun;65(6):623-5. doi: 10.1002/ana.21736.
10
Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS.载脂蛋白E:结构决定功能,从动脉粥样硬化到阿尔茨海默病再到艾滋病。
J Lipid Res. 2009 Apr;50 Suppl(Suppl):S183-8. doi: 10.1194/jlr.R800069-JLR200. Epub 2008 Dec 22.